# Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies

> **NCT02293941** · PHASE2 · TERMINATED · sponsor: **TaiwanJ Pharmaceuticals Co., Ltd** · enrollment: 54 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** JKB-122 5mg
- **DRUG:** JKB-122 15mg
- **DRUG:** JKB-122 35mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02293941
- **Lead sponsor:** TaiwanJ Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2017-08-30
- **Final completion:** 2017-08-30
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Completed stage I without pursuing stage II
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293941, "Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*